Article

FDA accepts Eylea sBLA

The FDA has accepted for standard review Regeneron Pharmaceuticals Inc.’s supplemental Biologics License Application (sBLA) of aflibercept (Eylea) for the treatment of diabetic macular edema (DME).

 

Tarrytown, NY-The FDA has accepted for standard review Regeneron Pharmaceuticals Inc.’s supplemental Biologics License Application (sBLA) of aflibercept (Eylea) for the treatment of diabetic macular edema (DME).

Under the Prescription Drug User Fee Act, the goal for a standard review of an sBLA is 10 months from submission, for a target action date of August 2014.

“Diabetes is a growing public health concern and DME is a leading cause of vision loss in patients with diabetic retinopathy,” said George D. Yancopoulos, MD, PhD, chief scientific officer for Regeneron and president of Regeneron Laboratories. “We hope to be able to offer a new treatment option to patients who suffer from DME.”

The aflibercept sBLA submission is based on positive results from phase III VIVID and VISTA trials.

The drug was approved in the United States for the treatment of neovascular (wet) age-related macular degeneration (AMD) in November 2011, and for macular edema following central retinal vein occlusion (CRVO) in September 2012.

The drug has also been approved in the European Union, Japan, Australia, and in several other countries for use in wet AMD, as well as by the European Commission and selected countries in Asia and Latin America for the treatment of visual impairment due to macular edema following CRVO.

Regulatory submissions have also been made in the European United for the drug in DME.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.